544 North Clin Istanb

Cite this article as: Ince V, Tasolar H, Yilmaz S. Attention for insertion of temporary cardiac pacemaker in liver transplant patients. North Clin Istanb 2021;8(5):543–544.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study has received no financial support.

Authorship Contributions: Concept – VI; Design – VI; Supervision – SY; Data collection and/or processing – VI, HT; Analysis and/or interpretation – VI, HT; Literature review – VI; Writing – VI; Critical review – VI, HT, SY.

REFERENCES

- Kobayashi T, Sato Y, Yamamoto S, Oya H, Takeishi T, Kokai H, et al. Temporary cardiac pacing for fatal arrhythmia in living-donor liver transplantation: three case reports. Transplant Proc 2008;40:2818–20.
- 2. Ramos J, Pai SL, Perry DK, Blackshear JL, Aniskevich S. Atrioventricular sequential pacing for hypertrophic cardiomyopathy during liver transplantation. A A Case Rep 2015;5:134–8.
- 3. Murata H, Inoue H, Sumikawa K. Anesthetic management of a patient undergoing liver transplantation who had previous coronary artery bypass grafting using an in situ right gastroepiploic artery. J Anesth 2010;24:264–7.

Correspondence: Volkan INCE, MD. Genel Cerrahi Anabilim Dali, Inonu Universitesi, Karaciger Nakli Enstitusu, Malatya, Turkey.

Tel: +90 422 3410660/6301 e-mail: volkanince@outlook.com

doi: 10.14744/nci.2020.59354

© Copyright 2021 by Istanbul Provincial Directorate of Health - Available online at www.northclinist.com



ICU admission and favipiravir

Rujittika Mungmunpuntipantip,¹ D Viroj Wiwanitkit²

¹Private Academic Consultant, Bangkok Thailand ²Honorary professor, Dr. DY Patil University Pune, India

To the Editor.

We would like to share ideas on "ICU admission rates in Istanbul following the addition of favipiravir to the national COVID-19 treatment protocol" [1]. Guner et al. [1] concluded that "The addition of favipiravir to the national

COVID-19 treatment protocol may explain this rapid decrease in the rate of ICU admissions and intubation. The favipiravir is the new hope for COVID-10 outbreak containment. However, the insufficiency and unavailability are main problems in many developing countries.

The decreased ICU described by Guner et al. [2] might be an effect of favipiravir use. However, it might also be the effect by other factors such as other infectious disease control process, a good supportive treatment, and seasonal fluctuation of disease incidence. Finally, a recent report also showed that an additional use of hydroxychloroquine plus favipiravir can provide a better outcome than favipiravir alone.

Cite this article as: Mungmunpuntipantip R, Wiwanitkit V. ICU admission and favipiravir. North Clin Istanb 2021;8(5):544.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study has received no financial support.

Authorship Contributions: Concept – RM, VW?; Design – RM, VW; Supervision – RM, VW; Funding – RM, VW; Materials – RM, VW; Data collection and/or processing – RM, VW; Analysis and/or interpretation – RM, VW; Literature review – RM, VW; Writing – RM, VW; Critical review – RM, VW.

REFERENCES

- Guner AE, Surmeli A, Kural K, Yilmaz H, Kocayigit E, Sahin E, et al. ICU admission rates in Istanbul following the addition of favipiravir to the national COVID-19 treatment protocol. North Clin Istanb 2021;8:119–23.
- 2. Guner R, Hasanoglu I, Kayaaslan B, Aypak A, Akinci E, Bodur H, et al. Comparing ICU admission rates of mild/moderate COVID-19 patients treated with hydroxychloroquine, favipiravir, and hydroxychloroquine plus favipiravir. J Infect Public Health 2021;14:365–70.

Correspondence: Rujittika MUNGMUNPUNTIPANTIP, MD. Private Academic Consultant, Bangkok, Thailand. Tel: +90 66247656787 e-mail: rujittika@gmail.com

doi: 10.14744/nci.2021.60234

© Copyright 2021 by Istanbul Provincial Directorate of Health - Available online a www.northclinist.com

